This activity is supported by an educational grant from: Argenx
Target-specific agents against B cells, complement and FcRn are promising in treating antibody-mediated neuromuscular diseases, even ensuring long-lasting remissions and excellent tolerance. The mechanism of action of these agents and potential biomarkers of response to therapies useful for the practicing neurologists, will be addressed.
This course will highlight emerging therapeutics for the treatment of Myasthenia Gravis, an immune mediated chronic disorder of neuromuscular transmission. Multiple limitations to current treatment strategies exist due to persistent disease burden with treatment and the associated treatment burden experienced by the patient. This talk will highlight two rapidly emerging treatments focusing on the inhibition of the neonatal Fc receptor (FcRn) and Complement protein C5 as potential strategies for the treatment of this disease.